Companies /Healthcare

Agios Pharmaceuticals Inc

NASDAQ: AGIO Biotechnology
$32.90
▼ $1.29 (−3.77%) today
Markets closed · 4:54pm ET

Fundamentals

Market Cap
$2.0B
Revenue (TTM)
$98.3M
EPS (TTM)
$-7.22
52-Week Range
$22 – $46
Street Target
$46.25

About Agios Pharmaceuticals

Agios Pharmaceuticals Inc is a pioneering biopharmaceutical company based in Cambridge, Massachusetts, focusing on creating innovative medicines that target cellular metabolism. Its flagship product, PYRUKYND, is a groundbreaking treatment for hemolytic anemias, activating specific enzymes to combat the disease. Agios is also developing treatments for myelodysplastic syndrome and phenylketonuria, alongside research into combating polycythemia vera, a rare blood disorder, through preclinical studies. Founded in 2007, Agios is at the forefront of addressing complex diseases with cutting-edge science.

AGIO Coverage

9:54am ET
Health and Healthcare

Agios Pharma’s Big Bet on Anemia

Agios Pharmaceuticals shares jumped on Monday after the company announced that it will be streamlining its portfolio.

Chris Lange